PSC
CPRX icon

Piper Sandler & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Piper Sandler & Co’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-50,000
Closed -$217K – 103
2015
Q1 		$217K Buy
+50,000
New +$180K 0.09% 90
2014
Q3 		– Sell
-50,000
Closed -$127K – 136
2014
Q2 		$127K Buy
+50,000
New +$107K 0.09% 83

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Piper Sandler & Co's CPRX Position: Q2 2015 in Review

Piper Sandler & Co sold out of Catalyst Pharmaceutical (CPRX) in Q2 2015, closing a stake of 50,000 shares — an estimated $217K sold.

Piper Sandler & Co first reported a position in CPRX in Q2 2014 and held it in 2 quarters. The position peaked at $217K in Q1 2015. 87 funds tracked by Wall St. Rank hold CPRX as of Q2 2015.

  • Piper Sandler & Co reported no remaining Catalyst Pharmaceutical position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 50,000 Catalyst Pharmaceutical shares in Q2 2015, an estimated $217K.
  • Piper Sandler & Co first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 2 quarters.
  • Piper Sandler & Co's Catalyst Pharmaceutical position peaked at $217K in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.